|
Synonyms: LY-3090106 | LY3090106
Compound class:
Antibody
Comment: Tibulizumab (LY3090106) is an investigational bispecific monoclonal antibody. It is a humanized antibody that simultaneously targets IL-17A and BAFF (TNFSF13B; CD257), that was produced by Eli Lilly as a potential therapeutic for IL-17-driven autoimmune diseases. Peptide sequences for tibulizumab (accessed from IMGT) are 100% matches with SEQ IDs 1 and 2 from patent WO2013158577A1, entitled 'Anti-baff-anti-il-17 bispecific antibodies' [1]. Tibulizumab neutralises IL-17 and BAFF bioactivities in vitro and in vivo [1].
|
| Immunopharmacology Comments |
| IL-17 is a validated target for inflammatory disease that are driven by Th17 cells and the IL-17 cytokine. BAFF has been implicated in the pathogenesis of autoimmune diseases in animal models. In addition BAFF promotes the expansion of Th17 cells, thus amplifying the production of proinflammatory IL-17. Hence simultaneous inhibition of IL-17 and BAFF bioactivities is considered as an expeditious mechanism by which to reduce pathological symptoms in autoimmune disease like rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome. Tibulizumab was designed to achieve this. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Sjögren's syndrome |
Orphanet:
ORPHA378 |
Phase 1 trial NCT02614716 in SS has been completed. | |
| Rheumatoid arthritis |
Disease Ontology:
DOID:7148 OMIM: 180300 |
Phase 1 clinical trial NCT01925157 in RA has been completed. | |
